AngelCentral successfully completed an angel syndicate investment in Pharmint, the largest B2B pharmaceutical platform aimed at improving access to affordable medicine in Southeast Asia, Latin America, and Africa.

Target Company Overview

Pharmint is recognized as the largest B2B pharmaceutical platform, successfully connecting thousands of pharmaceutical professionals and suppliers. By streamlining the supply chain, Pharmint enhances the accessibility of essential medications. The company's mission addresses a significant global challenge: the inadequate access to affordable medicine, particularly in regions such as Southeast Asia, Latin America, and Africa. Through its platform, Pharmint promotes price transparency, which is vital for ensuring that life-saving medicines are both affordable and authentic, thus combating issues like inflated prices and counterfeit products.

This investment serves as a catalyst for Pharmint to scale its operations and make a substantial impact in global healthcare. Guiding its efforts is their mission statement, which underscores the urgency of their work: "The poorest people in the world do not have access to the cheapest medicine, and that's the issue we're trying to solve."

Industry Overview

The pharmaceutical industry in Southeast Asia is characterized by rapid growth and increasing demand for quality healthcare solutions. As populations expand and healthcare needs evolve, the necessity for efficient dis